How Bellerophon Therapeutics is using IRT to successfully handle the multiple layers of complexity within a direct-to-Patient trial
How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials
As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges.
What you will learn
- Benefits and challenges associated with the Direct-to-Patient model
- Bellerophon's top considerations when implementing this trial design
- How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges